Gray matter atrophy in multiple sclerosis despite clinical and lesion stability during natalizumab treatment

Fredrika Koskimäki, Jacqueline Bernard, Jeong Yong, Nancy Arndt, Timothy Carroll, Seon Kyu Lee, Anthony T. Reder, Adil Javed

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Background Brain volume loss is an important surrogate marker for assessing disability in MS; however, contribution of gray and white matter to the whole brain volume loss needs further examination in the context of specific MS treatment. Objectives To examine whole and segmented gray, white, thalamic, and corpus callosum volume loss in stable patients receiving natalizumab for 2–5 years. Methods This was a retrospective study of 20 patients undergoing treatment with natalizumab for 24–68 months. Whole brain volume loss was determined with SIENA. Gray and white matter segmentation was done using FAST. Thalamic and corpus callosum volumes were determined using Freesurfer. T1 relaxation values of chronic hypointense lesions (black holes) were determined using a quantitative, in-house developed method to assess lesion evolution. Results Over a mean of 36.6 months, median percent brain volume change (PBVC) was -2.0% (IQR 0.99–2.99). There was decline in gray (p = 0.001) but not white matter (p = 0.6), and thalamic (p = 0.01) but not corpus callosum volume (p = 0.09). Gray matter loss correlated with PBVC (Spearman’s r = 0.64, p = 0.003) but not white matter (Spearman’s r = 0.42, p = 0.07). Age significantly influenced whole brain volume loss (p = 0.010, multivariate regression), but disease duration and baseline T2 lesion volume did not. There was no change in T1 relaxation values of lesions or T2 lesion volume over time. All patients remained clinically stable. Conclusions These results demonstrate that brain volume loss in MS is primarily driven by gray matter changes and may be independent of clinically effective treatment.

Original languageEnglish (US)
Article numbere0209326
JournalPloS one
Volume13
Issue number12
DOIs
StatePublished - Dec 1 2018

Fingerprint

sclerosis
atrophy
lesions (animal)
Multiple Sclerosis
Atrophy
Brain
Corpus Callosum
brain
Therapeutics
Patient treatment
Gray Matter
Natalizumab
Retrospective Studies
Biomarkers
White Matter
retrospective studies

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Agricultural and Biological Sciences(all)

Cite this

Gray matter atrophy in multiple sclerosis despite clinical and lesion stability during natalizumab treatment. / Koskimäki, Fredrika; Bernard, Jacqueline; Yong, Jeong; Arndt, Nancy; Carroll, Timothy; Lee, Seon Kyu; Reder, Anthony T.; Javed, Adil.

In: PloS one, Vol. 13, No. 12, e0209326, 01.12.2018.

Research output: Contribution to journalArticle

Koskimäki, F, Bernard, J, Yong, J, Arndt, N, Carroll, T, Lee, SK, Reder, AT & Javed, A 2018, 'Gray matter atrophy in multiple sclerosis despite clinical and lesion stability during natalizumab treatment', PloS one, vol. 13, no. 12, e0209326. https://doi.org/10.1371/journal.pone.0209326
Koskimäki, Fredrika ; Bernard, Jacqueline ; Yong, Jeong ; Arndt, Nancy ; Carroll, Timothy ; Lee, Seon Kyu ; Reder, Anthony T. ; Javed, Adil. / Gray matter atrophy in multiple sclerosis despite clinical and lesion stability during natalizumab treatment. In: PloS one. 2018 ; Vol. 13, No. 12.
@article{d4eee3b57fc94c0e916c254f297a8a83,
title = "Gray matter atrophy in multiple sclerosis despite clinical and lesion stability during natalizumab treatment",
abstract = "Background Brain volume loss is an important surrogate marker for assessing disability in MS; however, contribution of gray and white matter to the whole brain volume loss needs further examination in the context of specific MS treatment. Objectives To examine whole and segmented gray, white, thalamic, and corpus callosum volume loss in stable patients receiving natalizumab for 2–5 years. Methods This was a retrospective study of 20 patients undergoing treatment with natalizumab for 24–68 months. Whole brain volume loss was determined with SIENA. Gray and white matter segmentation was done using FAST. Thalamic and corpus callosum volumes were determined using Freesurfer. T1 relaxation values of chronic hypointense lesions (black holes) were determined using a quantitative, in-house developed method to assess lesion evolution. Results Over a mean of 36.6 months, median percent brain volume change (PBVC) was -2.0{\%} (IQR 0.99–2.99). There was decline in gray (p = 0.001) but not white matter (p = 0.6), and thalamic (p = 0.01) but not corpus callosum volume (p = 0.09). Gray matter loss correlated with PBVC (Spearman’s r = 0.64, p = 0.003) but not white matter (Spearman’s r = 0.42, p = 0.07). Age significantly influenced whole brain volume loss (p = 0.010, multivariate regression), but disease duration and baseline T2 lesion volume did not. There was no change in T1 relaxation values of lesions or T2 lesion volume over time. All patients remained clinically stable. Conclusions These results demonstrate that brain volume loss in MS is primarily driven by gray matter changes and may be independent of clinically effective treatment.",
author = "Fredrika Koskim{\"a}ki and Jacqueline Bernard and Jeong Yong and Nancy Arndt and Timothy Carroll and Lee, {Seon Kyu} and Reder, {Anthony T.} and Adil Javed",
year = "2018",
month = "12",
day = "1",
doi = "10.1371/journal.pone.0209326",
language = "English (US)",
volume = "13",
journal = "PLoS One",
issn = "1932-6203",
publisher = "Public Library of Science",
number = "12",

}

TY - JOUR

T1 - Gray matter atrophy in multiple sclerosis despite clinical and lesion stability during natalizumab treatment

AU - Koskimäki, Fredrika

AU - Bernard, Jacqueline

AU - Yong, Jeong

AU - Arndt, Nancy

AU - Carroll, Timothy

AU - Lee, Seon Kyu

AU - Reder, Anthony T.

AU - Javed, Adil

PY - 2018/12/1

Y1 - 2018/12/1

N2 - Background Brain volume loss is an important surrogate marker for assessing disability in MS; however, contribution of gray and white matter to the whole brain volume loss needs further examination in the context of specific MS treatment. Objectives To examine whole and segmented gray, white, thalamic, and corpus callosum volume loss in stable patients receiving natalizumab for 2–5 years. Methods This was a retrospective study of 20 patients undergoing treatment with natalizumab for 24–68 months. Whole brain volume loss was determined with SIENA. Gray and white matter segmentation was done using FAST. Thalamic and corpus callosum volumes were determined using Freesurfer. T1 relaxation values of chronic hypointense lesions (black holes) were determined using a quantitative, in-house developed method to assess lesion evolution. Results Over a mean of 36.6 months, median percent brain volume change (PBVC) was -2.0% (IQR 0.99–2.99). There was decline in gray (p = 0.001) but not white matter (p = 0.6), and thalamic (p = 0.01) but not corpus callosum volume (p = 0.09). Gray matter loss correlated with PBVC (Spearman’s r = 0.64, p = 0.003) but not white matter (Spearman’s r = 0.42, p = 0.07). Age significantly influenced whole brain volume loss (p = 0.010, multivariate regression), but disease duration and baseline T2 lesion volume did not. There was no change in T1 relaxation values of lesions or T2 lesion volume over time. All patients remained clinically stable. Conclusions These results demonstrate that brain volume loss in MS is primarily driven by gray matter changes and may be independent of clinically effective treatment.

AB - Background Brain volume loss is an important surrogate marker for assessing disability in MS; however, contribution of gray and white matter to the whole brain volume loss needs further examination in the context of specific MS treatment. Objectives To examine whole and segmented gray, white, thalamic, and corpus callosum volume loss in stable patients receiving natalizumab for 2–5 years. Methods This was a retrospective study of 20 patients undergoing treatment with natalizumab for 24–68 months. Whole brain volume loss was determined with SIENA. Gray and white matter segmentation was done using FAST. Thalamic and corpus callosum volumes were determined using Freesurfer. T1 relaxation values of chronic hypointense lesions (black holes) were determined using a quantitative, in-house developed method to assess lesion evolution. Results Over a mean of 36.6 months, median percent brain volume change (PBVC) was -2.0% (IQR 0.99–2.99). There was decline in gray (p = 0.001) but not white matter (p = 0.6), and thalamic (p = 0.01) but not corpus callosum volume (p = 0.09). Gray matter loss correlated with PBVC (Spearman’s r = 0.64, p = 0.003) but not white matter (Spearman’s r = 0.42, p = 0.07). Age significantly influenced whole brain volume loss (p = 0.010, multivariate regression), but disease duration and baseline T2 lesion volume did not. There was no change in T1 relaxation values of lesions or T2 lesion volume over time. All patients remained clinically stable. Conclusions These results demonstrate that brain volume loss in MS is primarily driven by gray matter changes and may be independent of clinically effective treatment.

UR - http://www.scopus.com/inward/record.url?scp=85058911746&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85058911746&partnerID=8YFLogxK

U2 - 10.1371/journal.pone.0209326

DO - 10.1371/journal.pone.0209326

M3 - Article

VL - 13

JO - PLoS One

JF - PLoS One

SN - 1932-6203

IS - 12

M1 - e0209326

ER -